Financhill
Buy
63

TECX Quote, Financials, Valuation and Earnings

Last price:
$53.98
Seasonality move :
-9.3%
Day range:
$52.95 - $61.07
52-week range:
$13.80 - $61.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.31x
Volume:
433.3K
Avg. volume:
364.1K
1-year change:
258.07%
Market cap:
$798.7M
Revenue:
--
EPS (TTM):
-$3.45

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TECX
Tectonic Therapeutic
-- -- -- -50.01% $74.67
AIM
AIM ImmunoTech
$100K -$0.09 -23.08% -53.85% $2.75
CI
The Cigna Group
$63.2B $7.82 8.7% 124.09% $370.25
CVM
CEL-SCI
-- -- -- -- $7.73
LLY
Eli Lilly and
$13.4B $5.16 49.68% 124.93% $972.77
TMCI
Treace Medical Concepts
$68.4M -$0.04 7.59% -69.22% $9.05
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TECX
Tectonic Therapeutic
$54.14 $74.67 $798.7M -- $0.00 0% --
AIM
AIM ImmunoTech
$0.20 $2.75 $12.9M -- $0.00 0% 55.49x
CI
The Cigna Group
$294.21 $370.25 $80.6B 24.04x $1.40 1.9% 0.34x
CVM
CEL-SCI
$0.39 $7.73 $28.8M -- $0.00 0% --
LLY
Eli Lilly and
$811.08 $972.77 $770B 87.68x $1.30 0.64% 17.95x
TMCI
Treace Medical Concepts
$10.05 $9.05 $626.1M -- $0.00 0% 3.07x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TECX
Tectonic Therapeutic
-- 1.340 -- --
AIM
AIM ImmunoTech
48.41% 0.854 17.25% 0.71x
CI
The Cigna Group
43.8% 1.702 -- 0.80x
CVM
CEL-SCI
-- 0.978 -- --
LLY
Eli Lilly and
68.61% 1.194 3.9% 0.63x
TMCI
Treace Medical Concepts
33.66% 4.379 14.74% 2.80x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TECX
Tectonic Therapeutic
-- -$19.6M -- -- -- -$42.4M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
CI
The Cigna Group
-- -- 4.58% 6.99% 2.5% -$353M
CVM
CEL-SCI
-- -$6.7M -- -- -- -$4.6M
LLY
Eli Lilly and
$9.3B $4.4B 21.5% 66.4% 15.57% -$458.9M
TMCI
Treace Medical Concepts
$36.1M -$15.1M -34.77% -49.68% -31.16% -$14.7M

Tectonic Therapeutic vs. Competitors

  • Which has Higher Returns TECX or AIM?

    AIM ImmunoTech has a net margin of -- compared to Tectonic Therapeutic's net margin of -10571.43%. Tectonic Therapeutic's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$1.20 --
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About TECX or AIM?

    Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 58.23%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 1262.06%. Given that AIM ImmunoTech has higher upside potential than Tectonic Therapeutic, analysts believe AIM ImmunoTech is more attractive than Tectonic Therapeutic.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    3 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is TECX or AIM More Risky?

    Tectonic Therapeutic has a beta of 1.198, which suggesting that the stock is 19.781% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of -0.292, suggesting its less volatile than the S&P 500 by 129.237%.

  • Which is a Better Dividend Stock TECX or AIM?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or AIM?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Tectonic Therapeutic's net income of -$17.7M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 55.49x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$17.7M
    AIM
    AIM ImmunoTech
    55.49x -- $35K -$3.7M
  • Which has Higher Returns TECX or CI?

    The Cigna Group has a net margin of -- compared to Tectonic Therapeutic's net margin of 2.17%. Tectonic Therapeutic's return on equity of -- beat The Cigna Group's return on equity of 6.99%.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$1.20 --
    CI
    The Cigna Group
    -- $5.13 $75.1B
  • What do Analysts Say About TECX or CI?

    Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 58.23%. On the other hand The Cigna Group has an analysts' consensus of $370.25 which suggests that it could grow by 26.47%. Given that Tectonic Therapeutic has higher upside potential than The Cigna Group, analysts believe Tectonic Therapeutic is more attractive than The Cigna Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    3 0 0
    CI
    The Cigna Group
    13 4 0
  • Is TECX or CI More Risky?

    Tectonic Therapeutic has a beta of 1.198, which suggesting that the stock is 19.781% more volatile than S&P 500. In comparison The Cigna Group has a beta of 0.541, suggesting its less volatile than the S&P 500 by 45.852%.

  • Which is a Better Dividend Stock TECX or CI?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cigna Group offers a yield of 1.9% to investors and pays a quarterly dividend of $1.40 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. The Cigna Group pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or CI?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than The Cigna Group quarterly revenues of $65.6B. Tectonic Therapeutic's net income of -$17.7M is lower than The Cigna Group's net income of $1.4B. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while The Cigna Group's PE ratio is 24.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 0.34x for The Cigna Group. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$17.7M
    CI
    The Cigna Group
    0.34x 24.04x $65.6B $1.4B
  • Which has Higher Returns TECX or CVM?

    CEL-SCI has a net margin of -- compared to Tectonic Therapeutic's net margin of --. Tectonic Therapeutic's return on equity of -- beat CEL-SCI's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$1.20 --
    CVM
    CEL-SCI
    -- -$0.14 --
  • What do Analysts Say About TECX or CVM?

    Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 58.23%. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 1888%. Given that CEL-SCI has higher upside potential than Tectonic Therapeutic, analysts believe CEL-SCI is more attractive than Tectonic Therapeutic.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    3 0 0
    CVM
    CEL-SCI
    1 0 0
  • Is TECX or CVM More Risky?

    Tectonic Therapeutic has a beta of 1.198, which suggesting that the stock is 19.781% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.122%.

  • Which is a Better Dividend Stock TECX or CVM?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or CVM?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Tectonic Therapeutic's net income of -$17.7M is lower than CEL-SCI's net income of -$6.9M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$17.7M
    CVM
    CEL-SCI
    -- -- -- -$6.9M
  • Which has Higher Returns TECX or LLY?

    Eli Lilly and has a net margin of -- compared to Tectonic Therapeutic's net margin of 8.48%. Tectonic Therapeutic's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$1.20 --
    LLY
    Eli Lilly and
    81.02% $1.07 $45.4B
  • What do Analysts Say About TECX or LLY?

    Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 58.23%. On the other hand Eli Lilly and has an analysts' consensus of $972.77 which suggests that it could grow by 19.94%. Given that Tectonic Therapeutic has higher upside potential than Eli Lilly and, analysts believe Tectonic Therapeutic is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    3 0 0
    LLY
    Eli Lilly and
    14 6 0
  • Is TECX or LLY More Risky?

    Tectonic Therapeutic has a beta of 1.198, which suggesting that the stock is 19.781% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.369%.

  • Which is a Better Dividend Stock TECX or LLY?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.64% to investors and pays a quarterly dividend of $1.30 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TECX or LLY?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Tectonic Therapeutic's net income of -$17.7M is lower than Eli Lilly and's net income of $970.3M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 87.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 17.95x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$17.7M
    LLY
    Eli Lilly and
    17.95x 87.68x $11.4B $970.3M
  • Which has Higher Returns TECX or TMCI?

    Treace Medical Concepts has a net margin of -- compared to Tectonic Therapeutic's net margin of -34.07%. Tectonic Therapeutic's return on equity of -- beat Treace Medical Concepts's return on equity of -49.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$1.20 --
    TMCI
    Treace Medical Concepts
    80.14% -$0.25 $158.1M
  • What do Analysts Say About TECX or TMCI?

    Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 58.23%. On the other hand Treace Medical Concepts has an analysts' consensus of $9.05 which suggests that it could fall by -9.95%. Given that Tectonic Therapeutic has higher upside potential than Treace Medical Concepts, analysts believe Tectonic Therapeutic is more attractive than Treace Medical Concepts.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    3 0 0
    TMCI
    Treace Medical Concepts
    1 6 0
  • Is TECX or TMCI More Risky?

    Tectonic Therapeutic has a beta of 1.198, which suggesting that the stock is 19.781% more volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock TECX or TMCI?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or TMCI?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than Treace Medical Concepts quarterly revenues of $45.1M. Tectonic Therapeutic's net income of -$17.7M is lower than Treace Medical Concepts's net income of -$15.4M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 3.07x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$17.7M
    TMCI
    Treace Medical Concepts
    3.07x -- $45.1M -$15.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is Intuitive Surgical Stock Surging?
Why Is Intuitive Surgical Stock Surging?

Surgeries are scary for lots of reasons, not least because…

Why Did Stanley Druckenmiller Buy ARS Pharmaceuticals?
Why Did Stanley Druckenmiller Buy ARS Pharmaceuticals?

Billionaire Stanley Druckenmiller has been making large changes to his…

Is CVS Health Stock Undervalued?
Is CVS Health Stock Undervalued?

CVS Health (NYSE:CVS) share price declined by over 23% over…

Stock Ideas

Buy
61
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 39x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Sell
38
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 101x

Alerts

Buy
54
DECK alert for Feb 3

Deckers Outdoor [DECK] is down 4.08% over the past day.

Sell
49
EXOD alert for Feb 3

Exodus Movement [EXOD] is up 26.96% over the past day.

Buy
73
DOGZ alert for Feb 3

Dogness (International) [DOGZ] is up 0.03% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock